Related Experiment Videos
Relaxin, a potent microcirculatory effector, is not angiogenic
International Journal of Microcirculation, Clinical and Experimental
|September 1, 1996
Summary
Relaxin (RLX) does not promote new blood vessel growth (angiogenesis) in mammals. This study found RLX ineffective in stimulating angiogenesis, which is crucial for tumor growth.
Area of Science:
- Physiology
- Vascular Biology
- Pharmacology
Background:
- Relaxin (RLX) is a known microcirculatory effector.
- Previous studies suggest RLX may have antitumor activity.
- Angiogenesis is essential for tumor growth and metastasis.
Purpose of the Study:
- To investigate the potential of relaxin (RLX) to induce de novo angiogenesis in vascularized mammalian tissue.
- To assess RLX's efficacy as an anti-angiogenic agent in vivo for potential cancer therapy.
Main Methods:
- The rat mesenteric-window angiogenesis assay was employed.
- Relaxin was administered intraperitoneally at varying doses (0.33, 3.3, 33 nM).
- Vascularized area and microvascular length were quantified using computer-aided microscopic morphometry.
Main Results:
- Relaxin (RLX) did not induce significant changes in vascularized area or microvascular density.
- No dose-dependent or time-dependent angiogenic effects were observed.
- RLX's inability to promote angiogenesis was confirmed in contrast to known angiogenic factors.
Conclusions:
- Relaxin (RLX) is not angiogenic in the tested mammalian model.
- This finding is significant for evaluating RLX's potential as an in vivo anticancer agent.
- RLX's lack of angiogenic properties suggests it may not support tumor growth.